Phoenixville Public Library will host a free virtual presentation, Pandemics and the Role of Biotechnology in Vaccine Development, on Thursday, October 1 at 7:00 PM. Yelena Fayvilevich will be the speaker.Join us for a candid exploration by a local scientist of the science behind the Covid-19 pandemic and vaccines. Learn how biotechnology addresses the treatment of viral and bacterial infections. Yelena will touch on the history of pandemics and their reflection in literature and art, while addressing the current situation with Covid-19 and Ebola and the progress of vaccine development for Covid-19. A question-and-answer period will follow.

Yelena Fayvilevich has over 34 years of experience in biotechnology and science education. She is a Senior Chemical Engineer at Merck, and also owns her own company, Biotechnology and Innovation, dedicated to science education and the popularization of science. She has developed STEM programs for private schools, adult senior centers, and summer camps. She has a Master's degree in chemical engineering and biotechnology, and is a member of the American Chemical Society and the International Society of Pharmaceutical Engineers.

This event is free and open to the public, and will be held online/by phone via Zoom. Registration is required at https://ccls.libcal.com/calendar/Phoenixville/biotechnologyor by calling 610-933-3013 x132. For more information, e-mail mpinto@ccls.org.

Follow this link:
Pandemics and the Role of Biotechnology in Vaccine Development - Patch.com

Vir Biotechnology, Inc. (NASDAQ:VIR) went down by -5.86% from its latest closing price when compared to the 1-year high value of $75.00 and move down -82.48%, while VIR stocks collected -20.79% of loss with the last five trading sessions. Press Release reported on 08/20/20 that Vir Biotechnology Presents Data on VIR-2218 from Clinical Studies for the Treatment of Hepatitis B at the EASL Digital International Liver Congress(TM)

Vir Biotechnology, Inc. (NASDAQ:VIR) 4 of the analysts out of 7 who provided ratings for Vir Biotechnology, Inc. stocks as a buy while 0 as overweight, 1 rated it as hold and 1 as sell. The average price we get from analysts is $49.17 which is $2.9 above current price. VIR currently has a short float of 3.60% and public float of 109.09M with average trading volume of 1.27M shares.

VIR stocks went down by -20.79% for the week, with the monthly drop of -13.42% and a quarterly performance of 20.25%. The simple moving average for the period of the last 20 days is -18.00% for VIR stocks with the simple moving average of 32.99% for the last 200 days.

Many brokerage firms have already submitted their reports for VIR stocks, with Needham repeating the rating for VIR shares by setting it to Buy. The predicted price for VIR socks in the upcoming period according to Needham is $62 based on the research report published on August 20, 2020.

JP Morgan, on the other hand, stated in their research note that they expect to see VIR stock at the price of $26. The rating they have provided for VIR stocks is Underweight according to the report published on March 19, 2020.

Goldman gave Neutral rating to VIR stocks, setting the target price at $26 in the report published on March 13, 2020.

After a stumble in the market that brought VIR to its low price for the period of the last 52 weeks, Vir Biotechnology, Inc. was unable to take a rebound, for now settling with -45.20% of loss for the given period.

The stock volatility was left at 6.78%, however, within the period of a single month, the volatility rate increased by 10.34%, while the shares sank at the distance of -12.66% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +10.84% upper at the present time.

In the course of the last 5 trading sessions, VIR went down by -20.79%, which changed the moving average for the period of 200 days to the total of +209.72% of gains for the stock in comparison to the 20-day moving average settled at $49.83. In addition, Vir Biotechnology, Inc. saw 226.84% in overturn over the period of a single year with a tendency to cut further gains.

Reports are indicating that there were more than several insider trading activities at Vir Biotechnology, Inc. (VIR), starting from Pang Phillip, who sold 12,500 shares at the price of $50.95 back on Aug 19. After this action, Rushing now owns 29,777 shares of Vir Biotechnology, Inc., valued at $636,855 with the latest closing price.

Virgin Herbert, the EVP, Research & CSO of Vir Biotechnology, Inc., sold 7,900 shares at the value of $51.08 during a trade that took place back on Aug 11, which means that Virgin Herbert is holding 0 shares at the value of $403,563 based on the most recent closing price.

The current profitability levels are settled at -2144.35 for the present operating margin. The net margin for Vir Biotechnology, Inc. stands at -2158.98. Total capital return value is set at -62.52, while invested capital returns managed to touch -62.97. Equity return holds the value -81.10%, with -42.30% for asset returns.

Based on Vir Biotechnology, Inc. (VIR), the companys capital structure generated 0.27 points for debt to equity in total, while total debt to capital is set at the value of 0.27.

Read more:
What Vir Biotechnology, Inc. (VIR) Doesnt Want You to Know - The News Heater

Plant Biotechnology Equipment Market Data and Acquisition Research Study with Trends and Opportunities 2019-2025The study of Plant Biotechnology Equipment market is a compilation of the market of Plant Biotechnology Equipment broken down into its entirety on the basis of types, application, trends and opportunities, mergers and acquisitions, drivers and restraints, and a global outreach. The detailed study also offers a board interpretation of the Plant Biotechnology Equipment industry from a variety of data points that are collected through reputable and verified sources. Furthermore, the study sheds a lights on a market interpretations on a global scale which is further distributed through distribution channels, generated incomes sources and a marginalized market space where most trade occurs.

Along with a generalized market study, the report also consists of the risks that are often neglected when it comes to the Plant Biotechnology Equipment industry in a comprehensive manner. The study is also divided in an analytical space where the forecast is predicted through a primary and secondary research methodologies along with an in-house model.

Request a sample of Plant Biotechnology Equipment Market report @ https://hongchunresearch.com/request-a-sample/60575

The following manufacturers are covered:Keygene(Netherlands)Heinz Walz GmbH (Germany)LemnaTec(Germany)Photon Systems Instruments(Czech Republic)Qubit Systems (Canada)Thermo Fisher Scientific (US)Tecan Group (Switzerland)LabRepCo (US)Geneq (Canada)Illumina (US)LGC Limited (UK)Evogene (Israel)

Access this report Plant Biotechnology Equipment Market @ https://hongchunresearch.com/report/worldwide-plant-biotechnology-equipment-market-2019-60575

Segment by RegionsNorth AmericaEuropeChinaJapan

Segment by TypeSensors ModulesImaging DevicesAutomated SystemDronesLED LightingPortable Devices

Segment by ApplicationPlant ResearchBreedingProduct DevelopmentQuality AssessmentOthers

For a global outreach, the Plant Biotechnology Equipment study also classifies the market into a global distribution where key market demographics are established based on the majority of the market share. The following markets that are often considered for establishing a global outreach are North America, Europe, Asia, and the Rest of the World. Depending on the study, the following markets are often interchanged, added, or excluded as certain markets only adhere to certain products and needs.

Here is a short glance at what the study actually encompasses:Study includes strategic developments, latest product launches, regional growth markers and mergers & acquisitionsRevenue, cost price, capacity & utilizations, import/export rates and market shareForecast predictions are generated from analytical data sources and calculated through a series of in-house processes.

However, based on requirements, this report could be customized for specific regions and countries.

To Check Discount of Plant Biotechnology Equipment Market @ https://hongchunresearch.com/check-discount/60575

Major Point of TOC:

Chapter One: Plant Biotechnology Equipment Market Overview

Chapter Two: Global Plant Biotechnology Equipment Market Competition by Manufacturers

Chapter Three: Global Plant Biotechnology Equipment Production Market Share by Regions

Chapter Four: Global Plant Biotechnology Equipment Consumption by Regions

Chapter Five: Global Plant Biotechnology Equipment Production, Revenue, Price Trend by Type

Chapter Six: Global Plant Biotechnology Equipment Market Analysis by Applications

Chapter Seven: Company Profiles and Key Figures in Plant Biotechnology Equipment Business

Chapter Eight: Plant Biotechnology Equipment Manufacturing Cost Analysis

Chapter Nine: Marketing Channel, Distributors and Customers

Chapter Ten: Market Dynamics

Chapter Eleven: Global Plant Biotechnology Equipment Market Forecast

Chapter Twelve: Research Findings and Conclusion

Chapter Thirteen: Methodology and Data Source 13.1 Methodology/Research Approach13.1.1 Research Programs/Design13.1.2 Market Size Estimation13.1.3 Market Breakdown and Data Triangulation13.2 Data Source13.2.1 Secondary Sources13.2.2 Primary Sources13.3 Author List13.4 Disclaimer

About HongChun Research:HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details:Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

Read more:
Impact Of Covid-19 on Plant Biotechnology Equipment Market 2020 Industry Challenges, Business Overview and Forecast Research Study 2026 - The Daily...

The global Agricultural Biotechnology market focuses on encompassing major statistical evidence for the Agricultural Biotechnology industry as it offers our readers a value addition on guiding them in encountering the obstacles surrounding the market. A comprehensive addition of several factors such as global distribution, manufacturers, market size, and market factors that affect the global contributions are reported in the study. In addition the Agricultural Biotechnology study also shifts its attention with an in-depth competitive landscape, defined growth opportunities, market share coupled with product type and applications, key companies responsible for the production, and utilized strategies are also marked.

This intelligence and 2026 forecasts Agricultural Biotechnology industry report further exhibits a pattern of analyzing previous data sources gathered from reliable sources and sets a precedented growth trajectory for the Agricultural Biotechnology market. The report also focuses on a comprehensive market revenue streams along with growth patterns, analytics focused on market trends, and the overall volume of the market.

Moreover, the Agricultural Biotechnology report describes the market division based on various parameters and attributes that are based on geographical distribution, product types, applications, etc. The market segmentation clarifies further regional distribution for the Agricultural Biotechnology market, business trends, potential revenue sources, and upcoming market opportunities.

Download PDF Sample of Agricultural Biotechnology Market report @ https://hongchunresearch.com/request-a-sample/72153

Key players in the global Agricultural Biotechnology market covered in Chapter 4:, Monsanto, KWS SAAT, Certis, Bayer CropScience, DuPont Pioneer Hi-Bred, Evogene, Dow AgroSciences, Syngenta, Mycogen Seeds., Vilmorin

In Chapter 11 and 13.3, on the basis of types, the Agricultural Biotechnology market from 2015 to 2026 is primarily split into:, Molecular Diagnostics, Molecular Markers, Tissue Culture, Vaccines, Genetic Engineering, Others

In Chapter 12 and 13.4, on the basis of applications, the Agricultural Biotechnology market from 2015 to 2026 covers:, Transgenic Crops, Synthetic Biology-Enabled Products, Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:, North America (Covered in Chapter 6 and 13), United States, Canada, Mexico, Europe (Covered in Chapter 7 and 13), Germany, UK, France, Italy, Spain, Russia, Others, Asia-Pacific (Covered in Chapter 8 and 13), China, Japan, South Korea, Australia, India, Southeast Asia, Others, Middle East and Africa (Covered in Chapter 9 and 13), Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Others, South America (Covered in Chapter 10 and 13), Brazil, Argentina, Columbia, Chile, Others

The Agricultural Biotechnology market study further highlights the segmentation of the Agricultural Biotechnology industry on a global distribution. The report focuses on regions of North America, Europe, Asia, and the Rest of the World in terms of developing business trends, preferred market channels, investment feasibility, long term investments, and environmental analysis. The Agricultural Biotechnology report also calls attention to investigate product capacity, product price, profit streams, supply to demand ratio, production and market growth rate, and a projected growth forecast.

In addition, the Agricultural Biotechnology market study also covers several factors such as market status, key market trends, growth forecast, and growth opportunities. Furthermore, we analyze the challenges faced by the Agricultural Biotechnology market in terms of global and regional basis. The study also encompasses a number of opportunities and emerging trends which are considered by considering their impact on the global scale in acquiring a majority of the market share.

The study encompasses a variety of analytical resources such as SWOT analysis and Porters Five Forces analysis coupled with primary and secondary research methodologies. It covers all the bases surrounding the Agricultural Biotechnology industry as it explores the competitive nature of the market complete with a regional analysis.

Brief about Agricultural Biotechnology Market Report with [emailprotected]https://hongchunresearch.com/report/agricultural-biotechnology-market-2020-72153

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Agricultural Biotechnology Market

Chapter Four: Players Profiles

Chapter Five: Global Agricultural Biotechnology Market Analysis by Regions

Chapter Six: North America Agricultural Biotechnology Market Analysis by Countries

Chapter Seven: Europe Agricultural Biotechnology Market Analysis by Countries

Chapter Eight: Asia-Pacific Agricultural Biotechnology Market Analysis by Countries

Chapter Nine: Middle East and Africa Agricultural Biotechnology Market Analysis by Countries

Chapter Ten: South America Agricultural Biotechnology Market Analysis by Countries

Chapter Eleven: Global Agricultural Biotechnology Market Segment by Types

Chapter Twelve: Global Agricultural Biotechnology Market Segment by Applications12.1 Global Agricultural Biotechnology Sales, Revenue and Market Share by Applications (2015-2020)12.1.1 Global Agricultural Biotechnology Sales and Market Share by Applications (2015-2020)12.1.2 Global Agricultural Biotechnology Revenue and Market Share by Applications (2015-2020)12.2 Transgenic Crops Sales, Revenue and Growth Rate (2015-2020)12.3 Synthetic Biology-Enabled Products Sales, Revenue and Growth Rate (2015-2020)12.4 Others Sales, Revenue and Growth Rate (2015-2020)

Chapter Thirteen: Agricultural Biotechnology Market Forecast by Regions (2020-2026) continued

Check [emailprotected] https://hongchunresearch.com/check-discount/72153

List of tablesList of Tables and FiguresTable Global Agricultural Biotechnology Market Size Growth Rate by Type (2020-2026)Figure Global Agricultural Biotechnology Market Share by Type in 2019 & 2026Figure Molecular Diagnostics FeaturesFigure Molecular Markers FeaturesFigure Tissue Culture FeaturesFigure Vaccines FeaturesFigure Genetic Engineering FeaturesFigure Others FeaturesTable Global Agricultural Biotechnology Market Size Growth by Application (2020-2026)Figure Global Agricultural Biotechnology Market Share by Application in 2019 & 2026Figure Transgenic Crops DescriptionFigure Synthetic Biology-Enabled Products DescriptionFigure Others DescriptionFigure Global COVID-19 Status OverviewTable Influence of COVID-19 Outbreak on Agricultural Biotechnology Industry DevelopmentTable SWOT AnalysisFigure Porters Five Forces AnalysisFigure Global Agricultural Biotechnology Market Size and Growth Rate 2015-2026Table Industry NewsTable Industry PoliciesFigure Value Chain Status of Agricultural BiotechnologyFigure Production Process of Agricultural BiotechnologyFigure Manufacturing Cost Structure of Agricultural BiotechnologyFigure Major Company Analysis (by Business Distribution Base, by Product Type)Table Downstream Major Customer Analysis (by Region)Table Monsanto ProfileTable Monsanto Production, Value, Price, Gross Margin 2015-2020Table KWS SAAT ProfileTable KWS SAAT Production, Value, Price, Gross Margin 2015-2020Table Certis ProfileTable Certis Production, Value, Price, Gross Margin 2015-2020Table Bayer CropScience ProfileTable Bayer CropScience Production, Value, Price, Gross Margin 2015-2020Table DuPont Pioneer Hi-Bred ProfileTable DuPont Pioneer Hi-Bred Production, Value, Price, Gross Margin 2015-2020Table Evogene ProfileTable Evogene Production, Value, Price, Gross Margin 2015-2020Table Dow AgroSciences ProfileTable Dow AgroSciences Production, Value, Price, Gross Margin 2015-2020Table Syngenta ProfileTable Syngenta Production, Value, Price, Gross Margin 2015-2020Table Mycogen Seeds. ProfileTable Mycogen Seeds. Production, Value, Price, Gross Margin 2015-2020Table Vilmorin ProfileTable Vilmorin Production, Value, Price, Gross Margin 2015-2020Figure Global Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure Global Agricultural Biotechnology Revenue ($) and Growth (2015-2020)Table Global Agricultural Biotechnology Sales by Regions (2015-2020)Table Global Agricultural Biotechnology Sales Market Share by Regions (2015-2020)Table Global Agricultural Biotechnology Revenue ($) by Regions (2015-2020)Table Global Agricultural Biotechnology Revenue Market Share by Regions (2015-2020)Table Global Agricultural Biotechnology Revenue Market Share by Regions in 2015Table Global Agricultural Biotechnology Revenue Market Share by Regions in 2019Figure North America Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure Europe Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure Asia-Pacific Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure Middle East and Africa Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure South America Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure North America Agricultural Biotechnology Revenue ($) and Growth (2015-2020)Table North America Agricultural Biotechnology Sales by Countries (2015-2020)Table North America Agricultural Biotechnology Sales Market Share by Countries (2015-2020)Figure North America Agricultural Biotechnology Sales Market Share by Countries in 2015Figure North America Agricultural Biotechnology Sales Market Share by Countries in 2019Table North America Agricultural Biotechnology Revenue ($) by Countries (2015-2020)Table North America Agricultural Biotechnology Revenue Market Share by Countries (2015-2020)Figure North America Agricultural Biotechnology Revenue Market Share by Countries in 2015Figure North America Agricultural Biotechnology Revenue Market Share by Countries in 2019Figure United States Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure Canada Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure Mexico Agricultural Biotechnology Sales and Growth (2015-2020)Figure Europe Agricultural Biotechnology Revenue ($) Growth (2015-2020)Table Europe Agricultural Biotechnology Sales by Countries (2015-2020)Table Europe Agricultural Biotechnology Sales Market Share by Countries (2015-2020)Figure Europe Agricultural Biotechnology Sales Market Share by Countries in 2015Figure Europe Agricultural Biotechnology Sales Market Share by Countries in 2019Table Europe Agricultural Biotechnology Revenue ($) by Countries (2015-2020)Table Europe Agricultural Biotechnology Revenue Market Share by Countries (2015-2020)Figure Europe Agricultural Biotechnology Revenue Market Share by Countries in 2015Figure Europe Agricultural Biotechnology Revenue Market Share by Countries in 2019Figure Germany Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure UK Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure France Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure Italy Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure Spain Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure Russia Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure Asia-Pacific Agricultural Biotechnology Revenue ($) and Growth (2015-2020)Table Asia-Pacific Agricultural Biotechnology Sales by Countries (2015-2020)Table Asia-Pacific Agricultural Biotechnology Sales Market Share by Countries (2015-2020)Figure Asia-Pacific Agricultural Biotechnology Sales Market Share by Countries in 2015Figure Asia-Pacific Agricultural Biotechnology Sales Market Share by Countries in 2019Table Asia-Pacific Agricultural Biotechnology Revenue ($) by Countries (2015-2020)Table Asia-Pacific Agricultural Biotechnology Revenue Market Share by Countries (2015-2020)Figure Asia-Pacific Agricultural Biotechnology Revenue Market Share by Countries in 2015Figure Asia-Pacific Agricultural Biotechnology Revenue Market Share by Countries in 2019Figure China Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure Japan Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure South Korea Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure Australia Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure India Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure Southeast Asia Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure Middle East and Africa Agricultural Biotechnology Revenue ($) and Growth (2015-2020) continued

About HongChun Research:HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details:Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

See original here:
Agricultural Biotechnology Market: Business Opportunities, Current Trends and Industry Analysis by 2020 to 2026 (Based on 2020 COVID-19 Worldwide...

School of Biotechnology

Dublin City University

Dublin City University http://www.dcu.ie is a research-intensive, globally-engaged, dynamic institution that is distinguished both by the quality and impact of its graduates and by its focus on the translation of knowledge into societal and economic benefit. Through its mission to transform lives and societies through education, research and innovation, DCU acts as an agent of social, cultural and economic progress. DCU is Irelands fastest growing university, and now hosts more than 17,000 students across its three academic campuses: DCU Glasnevin Campus, DCU St Patricks Campus and DCU All Hallows campus.

School of Biotechnology

The School of Biotechnology is the academic unit leading life science and biotechnology education and research within the Faculty of Science & Health at Dublin City University (DCU). The school delivers both undergraduate B.Sc and taught M.Sc. postgraduate degree programmes in addition to the education and training of research M.Sc. and Ph.D students under its structured Ph.D programme BioTranslate. It is an active centre of basic, applied and multi-disciplinary research, supporting a defined cluster of intersecting research themes which link closely with the Schools teaching programmes. The School and associated research centres (including the National Institute for Cellular Biotechnology (NICB nicb.ie) and the Water Institute (dcuwater.ie)) offer core facilities and technical support in the areas of Molecular Biology, Bioinformatics, Cell Characterisation, Proteomics, Bioprocessing, Sensor, Analytical Separations and membrane technology. Research projects fall into the general categories of Life Science or Industry-associated with activity in the domains of Health/Ageing/Disease, Biodesign, Environmental Science and Precision Health. They bring together a critical mass of multidisciplinary researchers that are strategically positioned to pursue national and international opportunities for research and innovation. The excellence of the schools research is reflected by funding success from many national and international sources (including direct funds from industry) and the quality of its published and other outputs.

Role Profile

The School is seeking to recruit an Assistant Professor in Biotechnology. The post holder will be expected to contribute to teaching, curriculum development, research, and administrative activities in the School, across all levels. The post holder will also be expected to contribute directly to degree programmes through research-led teaching, student mentoring and supervision of student projects.

Duties and Responsibilities

The duties and responsibilities of this post falls within DCUs Academic Development and Promotions Framework and the principles of the Schools Academic Workload Model with activity across the domains of teaching and learning, research and scholarship, and service and contribution. They are in line with DCUs strategic plan Talent, Discovery and Transformation: 2017-2022.

Teaching and Learning

This post will support the delivery of the Education mission of the University; specifically the delivery of the Schools two core undergraduate programmes, namely the B.Sc in Biotechnology and B.Sc in Genetics & Cell Biology and its substantial contribution to the B.Sc in Analytical Science and B.Sc. in Environmental Science & Technology, in addition to its two taught Masters programmes: M.Sc in Bioprocess Engineering and M.Sc in Diagnostics & Precision Medicine plus our service teaching to support other degree programmes. The School is committed to a flexible mode of module delivery across all of its programmes and the successful candidate(s) will be expected to develop on-line components to their assigned teaching modules. Teaching duties also include the design, supervision and delivery of undergraduate/postgraduate student projects.

Research and Scholarship

In addition to a demonstrable teaching ability, the post holder will be expected to have an independent research profile and the ability to secure grant awards from national/international agencies and/or industry to fund their research activities which would include the recruitment of both postgraduate students and postdoctoral research fellows; contribute to existing School/Centre and DCU-wide research initiatives and expand their network within DCU, nationally and internationally.

Service and Contribution to University

The post holder will be required to undertake administrative roles related to the activities of the School of Biotechnology and the Faculty of Science & Health as assigned by the Head of School. These roles may include but are not limited to the following: Programme Chair; School Executive member; Convenor roles (teaching, research or international), Faculty Management board, Marketing, Safety Committee, Open Days, Conference organisation, Work Placement Tutoring. Participation in courses provided by the University designed to develop skills in such areas as teaching, management and safety will also be expected.

Candidate Requirements

Mandatory Training

The post holder will be required to undertake the following mandatory compliance training: GDPR, Orientation, and Compliance.

Read the original here:
Assistant Professor in Biotechnology job with DUBLIN CITY UNIVERSITY | 210110 - Times Higher Education (THE)

The Advancements in the Marine Biotechnology Market Anticipates the Growth of the Market in the Coming Years

Market Research Storehas published a new report on the globalMarine Biotechnology market. The Marine Biotechnology market is slated to reach USD XX Million by 2026, expecting to exhibit a CAGR of XX% during the forecast period 2020 to 2026. The factors such as technological developments, supportive government initiatives, and the investments in the research and development activities aid for the Marine Biotechnology market development.

Click Here To Access The Free Sample PDF Report (including COVID-19 Impact Analysis, full TOC, Tables and Figures):http://www.marketresearchstore.com/report/global-marine-biotechnology-industry-market-report-2019-industry-647423#RequestSample

Major Market Players for Marine Biotechnology market areBioLume(r), Inc. (US), NovaMatrix (Norway), PML Applications Ltd. (UK), Marinova Pty Ltd (Australia), Cyanotech Corp. (US), Jazz Pharmaceuticals plc (Ireland), BASF SE (Germany), OceanBASIS GmbH (Germany), Royal DSM N.V (Netherlands), PharmaMar S.A (Spaiamong others.

Main Points Covered in the Report:

The complete market statistics both in terms of revenue and volume. Complete analysis about the Marine Biotechnology market dynamics, which includes the growth factors, restraints, challenges, and opportunities. Detailed information about the key industry players, their primary competencies, and the Marine Biotechnology market share. Strengths of the buyers and suppliers which will help clients for improving their decision-making skills.

Full Research Report Now::http://www.marketresearchstore.com/report/global-marine-biotechnology-industry-market-report-2019-industry-647423

Report Details include:

The current trends in the global Marine Biotechnology market, which includes comprehensive analysis on the manufacturer and consumer trends. Overview about the supply analysis, which includes complete information about suppliers, raw material, distributors, and others. Primary areas of investment identified by the research analysts and market experts to improve the market opportunities in the forecast period. Competitive landscape of the market players operating in the Marine Biotechnology market coupled with the strategic management. Company profiles of all the players operating in the Marine Biotechnology market.

Market Segmentation includes{Marine Animal Technolog, Marine Plant Technology}; {Foods, Nutraceuticals, Medicine, Cosmetics, Research Tools, Processing Technologies, New Energy Sources, Agriculture, Industrial, Food Safety}

Regional Segmentation

Asia Pacific Europe North America Latin America Middle East and Africa

For Any Query Regarding the Marine Biotechnology Market Report? Contact Us at@http://www.marketresearchstore.com/report/global-marine-biotechnology-industry-market-report-2019-industry-647423#InquiryForBuying

Key Questions Answered in the Report Include:

What will the market size and the growth rate be in 2026? What are the key factors driving the global Marine Biotechnology Market? What are the key market trends impacting the growth of the global Marine Biotechnology Market? What are the challenges to market growth? Who are the key vendors in the global Marine Biotechnology Market? What are the market opportunities and challenges faced by the vendors in the global Marine Biotechnology Market? What are the key outcomes of the five forces analysis of the global Marine Biotechnology Market?

The rest is here:
Global Marine Biotechnology Market Forecast Revised in a New Market Research Store Report as COVID-19 Projected to Hold a Massive Impact on Sales in...

"Agricultural Biotechnology Market"

Agricultural Biotechnology Market: Information by Crop Type (Soybean, Maize, Cotton, and others), Application (Herbicide Tolerance, Stacked Traits, Insect Tolerance, and others), Technique (Genetic Engineering, Molecular Breeding, Molecular Diagnostics and Tissue Culture) and Region (Americas, Europe, Asia-Pacific, and the Middle East & Africa) - Global Forecast till 2022

Global agricultural biotechnology market, including growth rate, key domains, segmentation, etc

The international agricultural biotechnology market is speculated to witness growth at CAGR of 10.10% by 2022. It was estimated to be worth USD 27,778.64 Million in 2018. Agricultural biotechnology market is considered as one of the swiftly advancing segments due to growing cultivation of biotechnology-based products. The growing level of investment in research and development is also touted as among the prime reasons behind the significant prospect of the market all throughout. With growing entrepreneurial emphasis, the market is speculated to advance in a much effective fashion.

Get a FREE Sample with Complete TOC By Considering the COVID-19 impact on Global Market @https://www.marketresearchfuture.com/sample_request/8724

Demand for agricultural biotechnology is witnessing consistent growth. This can be realized through the growing level of cultivation of the biotech crops. Moreover, cultivation has grown all across the globe. In fact, this aspect is speculated to enhance the growth of the international agricultural biotechnology market. It can be seen the level of demand for genetically modified crops has grown in a great way. Especially, the growth has been witnessed in developed parts like Europe.

The international zone for the biotechnology crops was around 190 million hectares, which was 185 million in 2016. In short, the level of cultivation is steadily growing and is expected to remain constant during the forecast period. The amount of land acquired and used for these purposes has grown in all parts, including the US. Above all, more than 70 nations have accepted the biotech crop cultivation. To be specific, India, US, Brazil, Argentina, and Canada are among the leading names in this context.

Agricultural Biotechnology Market Segmentation

International Agricultural Biotechnology Industry can be segmented on the basis of crop Type, Application, And Technique. On the basis of crop type, the global agricultural biotech market can be segmented into soybean, maize, cotton, and others. On the basis of application, the international agricultural biotechnology market is segmented into herbicide tolerance, stacked traits, insect tolerance, and others. In terms of technique, the international agricultural biotechnology is divided into genetic engineering, molecular breeding, molecular diagnostics, and tissue culture. Similarly, the market is segmented on the basis of region as well, is divided into the US, Europe, Asia Pacific, Middle East, and Africa.

Agricultural Biotechnology Market Regional Analysis

On the basis of region, the international agricultural biotech market is segmented into the US, Europe, Asia-Pacific, Middle East, and Africa. The US is considered the global leader in the agricultural biotechnology industry. A consistent boost in the cultivation of biotech crops is said to be the key reason behind the growth.

Asia-Pacific is among the other, a swiftly growing region in the global market. To be specific, the Indian market is the most prominent in this segment. Japan also shows great prospects. UK and Germany are leading European nations. The most significant among others are the African and Middle East market touted to be the most promising.

Agricultural Biotechnology Market Key Players

The Prominent Players in the GlobalAgricultural Biotechnology MarketareArcadia Biosciences (US)., Thermo Fisher Scientific (US), Bayer AG (Germany), Biocentury Transgene Co., Ltd (China), Vilmorin & Cie (France), Eurofins Scientific (Luxembourg), LGC Biosearch Technologies (US), Corteva Agriscience ( US), Dr. Chip Biotech Inc. (Taiwan), Evogene Ltd (Israel), and Yield10 Bioscience, Inc. (US).

Agricultural Biotechnology Industry news

Cole of Duty publishes reports on the global growth perspective of the agricultural biotechnology market. The report figures out all the crucial aspects associated with the market contributing to the market. It also identifies the key domains where the growth prospect is expected to be the most significant. It thus provides wholesome analysis on each aspect associated with the market.

TABLE OF CONTENT1 EXECUTIVE SUMMARY$ 1,350.002 MARKET INTRODUCTION $ 0.003 RESEARCH METHODOLOGY $ 0.004 MARKET DYNAMICS$ 950.005 MARKET FACTOR ANALYSIS$ 950.006 GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET, BY CROP TYPE$ 1,650.007 GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET, BY APPLICATION$ 1,650.008 GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET, BY TECHNIQUE$ 1,650.009 GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET, BY REGION

...Continued

LIST OF TABLES$TABLE 1 MARKET SYNOPSIS 13TABLE 2 LIST OF ASSUMPTIONS 15TABLE 3 COUNTRY SCENARIO OF GENETICALLY MODIFIED ORGANISM (GMO) CROPS PROHIBITION 28TABLE 4 GLOBAL AGRICUTURAL BIOTECHNOLOGY MARKET, BY CROP TYPE 2013-2022 (USD MILLION) 35TABLE 5 GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET, FOR SOYBEAN, BY REGION 2013-2022 (USD MILLION) 35TABLE 6 GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET, FOR MAIZE, BY REGION 2013-2022 (USD MILLION) 35TABLE 7 GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET, FOR MEDIUMTHROUGHPUT, BY REGION 2013-2022 (USD MILLION) 36TABLE 8 GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET, FOR OTHER CROPS, BY REGION 2013-2022 (USD MILLION) 36TABLE 9 GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET, BY APPLICATION 2013-2022 (USD MILLION) 38

...Continued

LIST OF FIGURES$FIGURE 1 GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET STRUCTURE 15FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES 21FIGURE 3 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET 24FIGURE 4 GLOBAL AREA OF BIOTECH CROPS, BY REGION, 20152017 (MILLION HECTARES) 25FIGURE 5 CULTIVATION AREA OF BIOTECH CROPS, BY COUNTRY, 2016 & 2017 (MILLION HECTARES) 26FIGURE 6 DRIVERS IMPACT ANALYSIS 27FIGURE 7 RESTRAINT IMPACT ANALYSIS 28FIGURE 8 PORTERS FIVE FORCES ANALYSIS: GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET 30FIGURE 9 VALUE CHAIN ANALYSIS OF THE GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET 32

...Continued

Obtain Premium Research Report Details, Considering the impact of COVID-19 @https://www.marketresearchfuture.com/reports/agricultural-biotechnology-market-8724

About Market Research Future:

AtMarket Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Media ContactCompany Name: Market Research FutureContact Person: Abhishek SawantEmail: Send EmailPhone: +1 646 845 9312Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar City: PuneState: MaharashtraCountry: IndiaWebsite: http://www.marketresearchfuture.com/reports/agricultural-biotechnology-market-8724

Original post:
Coronavirus (COVID-19) Impact on Agricultural Biotechnology Market 2020: Sales, Revenue of Top Companies, Emerging Technology Trends, Future Scope of...

Acer Therapeutics Inc (ACER) is around the middle of the Biotechnology industry according to InvestorsObserver. ACER received an overall rating of 49, which means that it scores higher than 49 percent of all stocks. Acer Therapeutics Inc also achieved a score of 36 in the Biotechnology industry, putting it above 36 percent of Biotechnology stocks. Biotechnology is ranked 11 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Acer Therapeutics Inc (ACER) stock is trading at $3.18 as of 11:42 AM on Monday, Jun 15, a decline of -$0.09, or -2.75% from the previous closing price of $3.27. The stock has traded between $3.02 and $3.27 so far today. Volume today is low. So far 53,121 shares have traded compared to average volume of 346,979 shares.

To see the top 5 stocks in Biotechnology click here.

Read the original:
Where Does Acer Therapeutics Inc (ACER) Stock Fall in the Biotechnology Field? - InvestorsObserver

The 67 rating InvestorsObserver gives to Novavax, Inc. (NVAX) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 66 percent of stocks in the Biotechnology industry, NVAXs 67 overall rating means the stock scores better than 67 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 67 means the stock is more attractive than 67 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Novavax, Inc. (NVAX) stock is lower by -5.21% while the S&P 500 has gained 0.13% as of 3:24 PM on Thursday, May 21. NVAX has fallen -$2.75 from the previous closing price of $52.81 on volume of 4,757,063 shares. Over the past year the S&P 500 has risen 4.17% while NVAX has gained 727.44%. NVAX lost -$4.14 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

Excerpt from:
Where Does Novavax, Inc. (NVAX) Stock Fall in the Biotechnology Field? - InvestorsObserver

PHOENIX--(BUSINESS WIRE)-- BioLab, Inc., a regenerative biotechnology company, today announced a partnership with Red One Medical that will help veterans and active military members access breakthrough wound healing and regenerative medicine.

Red One Medical is private sector innovation partner of Department of Veterans Affairs (VA) and Department of Defense (DoD) hospitals. As a Service-Disabled Veteran-Owned Small Business (SDVOSB), it provides advanced medical and pharmaceutical technologies that improve patient care for America's military veterans. BioLab Sciences is working with Red One Medical to distribute regenerative medicine products and MyOwn Skin, a novel biotechnology that can accelerate the healing of severe burns, chronic wounds, diabetic foot ulcers, and other difficult-to-heal wounds.

Nearly one in four veterans has diabetes, and as such, the need for an innovative wound care solution is critical to treat non-healing diabetic ulcersthe leading cause of lower-limb amputations in non-combat veterans.

Were constantly on the lookout for innovative products to speed wound healing in veteran and military hospitals," said Red One Medical CEO and Founder Charles Pollak. "We want our veterans to receive top quality care, and MyOwn Skin takes wound care to the next level by leveraging a patient's own skin to quickly grow skin grafts in a new, non-invasive way."

MyOwn Skin leverages a very small sample of a patient's skin and blood taken through a non-surgical procedure to reproduce three, 100cm2 skin grafts within a week. MyOwn Skin eliminates the need for traditional skin grafts which require surgical procedures to remove large areas of healthy skin from other parts of a patients body, often resulting in additional wounds requiring care and healing time.

We are on a mission to help patients and providers access regenerative medicine products that help the body achieve optimal performance, said BioLab Sciences President and CEO Bob Maguire. As the VAs private sector innovation partner, Red One Medical is in a unique position to help advance the delivery of care to our nations veteran and military patients. This partnership is one step forward in that direction.

Along with MyOwn Skin, which is now one of the most advanced products in Red One Medical's wound care portfolio, the company will also distribute BioLab Sciences amniotic allograft membrane, amniotic liquid allograft and other regenerative products that promote healing for wound, orthopedic, respiratory and ophthalmic care. The products will be available to the DoD and VA health system, which includes more than 9 million veterans at approximately 1,700 facilities.

About BioLab Sciences

BioLab Sciences is a regenerative medicine company focused on creating new ways to heal the body. Headquartered in Scottsdale, Arizona, BioLab Sciences is uncovering better ways to address orthopedic injuries, wound care, pain management, aesthetic medicine, respiratory ailments, cardiovascular indications, ophthalmic issues, and more. BioLab Sciences is transforming wound care through MyOwn Skin, a remarkable biotechnology that leverages a small sample of a patient's own skin from a non-surgical procedure to produce up to three 4-inch x 4-inch skin grafts in a week. Learn more at http://www.biolabsciences.net/.

About Red One Medical

Red One Medical is a private sector innovation partner of Department of Veterans Affairs (VA) medical centers and Department of Defense (DoD) hospitals. Red One Medical identifies and delivers advanced medical and pharmaceutical technologies that transform care for Americas military veterans. Located in Savannah, GA, Red One Medical is a CVE-certified Service Disabled Veteran Owned Business (SDVOSB) and SBA-certified Historically Underutilized Business Zone (HUBZone) company. It donates a portion of profits to charities that support veterans, military families and their communities.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200520005189/en/

Go here to read the rest:
BioLab Sciences Partners with Red One Medical to Provide Transformative Wound Healing Products to Veterans and Active Military - BioSpace

Global Biotechnology Reagents Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level.

Biotechnology Reagents Market Size Covers Global Industry Analysis, Size, Share, CAGR, Trends, Forecast And Business Opportunity.

>>Need a PDF of the global market report? Visit: https://industrystatsreport.com/Request/Sample?ResearchPostId=12804&RequestType=Sample

Global Biotechnology Reagents Market is valued at USD 71.25 Billion in 2018 and expected to reach USD 121.06 Billion by 2025 with the CAGR of 7.86% over the forecast period.

Increasing prevalence of diseases such as hepatitis B with growing research and development expenditure bybiotechnologytherapeutics and rising number of biotechnology firms globally are expected to boost the market over the forecast period.

Biotechnology reagents are the substances or compounds used to detect or create an additional substance in order to provide a test reading. Hence, the biotechnologies are used in research fields of genetics, molecular biology, diagnosis, immunology, bioscience and in education. The various uses of biotechnology reagents are; fluorescent microscopy, DNA analysis, immuno phenotyping and cell cycle analysis. The biotechnology reagents industry depends on the growth of biotechnology instrumentation market. Biotechnology reagents market includes technologies such as IVD, PCR, transfection, gene expression and cell culture. The basis of technology market is section into analytical reagents and life science reagents. The Life science technologies include in vitro diagnostics, unit culture, polymerase chain reaction and analytical technologies includes flow cytometry, electrophoresis, mass spectrometry and chromatography. The healthcare biotechnology is usually to improve medicines due to the advantages and pieces of knowledge it provides such as understanding the genetic composition of the human species, foundational structure of hereditary diseases manipulation and repairing of damaged genes to cure diseases. As the researchers might see the engineering of a supercharged flu virus as a perfectly reasonable way to better understand and thus fight the flu, the public might see the drawbacks as equally obvious the virus could escape, or someone could weaponize the research and the advanced genetic tools that some are considering for mosquito control could have unforeseen effects, possibly leading to environmental damage. Although the risks of biotechnology have been fretted over for decades, the increasing pace of progress from low cost DNA sequencing to rapid gene synthesis to precision genome editing suggests biotechnology is entering a new realm of maturity regarding both beneficial relevance and more worrisome risks.

Global Biotechnology Reagents Market report is segmented on the basis of type, application, and by regional & country level. Based on type, global biotechnology reagents market is classified as the Life science and analytical. Based upon application, global biotechnology reagents are classified into protein synthesis and purification, gene expression, DNA and RNA analysis and drug testing.

The regions covered in this biotechnology reagents market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of biotechnology reagents is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Key Players for Global Biotechnology Reagents Market Report-

Some major key players for Global Biotechnology Reagents Market are Life Technologies, Bio-Rad, Thermo Fisher Scientific, Water Corporation, Sigma-Aldrich Agilent Technologies Inc., Beckman Coulter, Roche, Abbott and others.

Global Biotechnology Reagents Market Dynamics

The rapidly increasing use of biotechnology reagents in therapeutics, basic research and its commercialization are the major factors responsible for the growth of this market. According to the World Health Organization (WHO) in 2017, prevalence of hepatitis B estimated about 27 million people 10.5% of all people estimated to be living with hepatitis B were aware of their infection, while 4.5 million around 16.7% of the people diagnosed were on treatment. Hence, the rising prices of DNA sequencing is predictable to serve this sector as a high impact rendering growth is expected to encourage researchers and manufacturers to increase R&D initiatives targeted at understanding genetic variations and developing therapeutic solutions for chronic diseases with large global prevalence such as cardiovascular diseases, diabetes, and cancer. According to the World Health Organization (WHO) in 2015, the estimates that in 257 million people were living with chronic hepatitis B infection as surface antigen positive, the hepatitis B resulted in an estimated 887 000 deaths, mostly from cirrhosis and hepatocellular carcinoma is primary liver cancer. In addition, the high investments in R&D activities, growing biomedical research, increasing number of biotechnology firms and advancement in stem cell research have contributed to the growth of the biotechnology reagents market.

The biotechnology organizations such as the department of biotechnology (DBT) with government funded institutions and other autonomous organizations representing the biotechnology sector, promote funding to support R&D and innovative produce development endeavors. One of the major challenges faced by this market use of biotechnology reagents in the field of drug discovery is an emerging market where proteomics, DNA chips, combinatorial chemistry, and high throughput screening enjoy the spotlight. In addition, high price of biopharmaceuticals may likely to restrain the growth of the biotechnology reagents market. Moreover, increase in the number of biotechnology firms around the globe and increase in research and development expenditure by the biotechnology corporation can provide various opportunities for the further growth of the market. The technological advancements and new product launches in health care and life science industries to life science reagents are an integral part of any clinical diagnostic laboratory and pharmaceutical & biotechnology industry. The recent technological advancements in molecular biology, life sciences, and biotechnology has brought about drastic changes in various fields such as medical diagnostics, drug discovery, personalized medicines, forensic sciences, and clinical research & development of the biotechnology reagents market.

Global Biotechnology Reagents Market Regional Analysis

Geographically,North America dominates the global biotechnology reagents market & incurs the highest expenditure for global R&D. According to the World Health Organization (WHO) in 2018, the chronic diseases in the United States are about 133 million Americans 45% of the population have at least one chronic disease. In addition, rising ongoing research in biological sciences considerable investments by various biotechnology companies and the consistently increasing utilization of biotechnology reagents in the market due to the continuing research and outsourcing activities in the field of life science in this region are also supplementing the market growth.

TheAsia Pacific is expected to show a lucrative growth rate during the forecast period due to increasing research and outsourcing activities in life science field. However, the regionlarge population, presence of emerging economies such as China and India, large number of elderly individuals in Japan presents significant opportunities for global players in these countries. Adoption of technologically advanced products in Japan, China, South Korea, Malaysia, and Singapore are likely to fuel the growth of the life science reagents market in this region. Moreover, increased investment by leading pharmaceutical and biotechnology companies in India and China, and rapidly increasing number of hospitals and diagnostic laboratories in the region boost the growth of the biotechnology reagents market in the region.

Key Benefits for Global Biotechnology Reagents Market Report

Global market report covers in depth historical and forecast analysis.

Global market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.

Global market report helps to identify opportunities in market place.

Global market report covers extensive analysis of emerging trends and competitive landscape.

By Type

By Application

By Regional & Country Analysis

Need a PDF of the global market report? Visit: https://industrystatsreport.com/Request/Sample?ResearchPostId=12804&RequestType=Methodology

Table of Content:

Market Overview: The report begins with this section where product overview and highlights of product and application segments of the Global Biotechnology Reagents Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company: Here, the competition in the Worldwide Global Biotechnology Reagents Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data: As the name suggests, this section gives the sales data of key players of the Global Biotechnology Reagents Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the Global Biotechnology Reagents Market.

Market Status and Outlook by Region: In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the Global Biotechnology Reagents Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User: This section of the research study shows how different end-user/application segments contribute to the Global Biotechnology Reagents Market.

Market Forecast: Here, the report offers a complete forecast of the Global Biotechnology Reagents Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion: This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

More:
COVID 19 PANDEMIC: Biotechnology Reagents Market is poised to achieve continuing growth During Forecast Period 2020-2026 - Cole of Duty

Vir Biotechnology, Inc. (NASDAQ:VIR) came out with its quarterly results last week, and we wanted to see how the business is performing and what industry forecasters think of the company following this report. Revenues came in 95% better than analyst models expected, at US$5.7m, although statutory losses ballooned 47% to US$0.71, which is much worse than what was forecast. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.

See our latest analysis for Vir Biotechnology

NasdaqGS:VIR Past and Future Earnings May 14th 2020

Taking into account the latest results, the most recent consensus for Vir Biotechnology from four analysts is for revenues of US$12.9m in 2020 which, if met, would be a sizeable 27% increase on its sales over the past 12 months. The loss per share is expected to greatly reduce in the near future, narrowing 39% to US$2.46. Before this latest report, the consensus had been expecting revenues of US$13.1m and US$2.03 per share in losses. While this year's revenue estimates held steady, there was also a loss per share expectations, suggesting the consensus has a bit of a mixed view on the stock.

As a result, there was no major change to the consensus price target of US$32.00, with the analysts implicitly confirming that the business looks to be performing in line with expectations, despite higher forecast losses. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. Currently, the most bullish analyst values Vir Biotechnology at US$44.00 per share, while the most bearish prices it at US$17.00. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Vir Biotechnology's past performance and to peers in the same industry. For example, we noticed that Vir Biotechnology's rate of growth is expected to accelerate meaningfully, with revenues forecast to grow 27%, well above its historical decline of 15% a year over the past year. Compare this against analyst estimates for the wider industry, which suggest that (in aggregate) industry revenues are expected to grow 24% next year. So it looks like Vir Biotechnology is expected to grow at about the same rate as the wider industry.

The most important thing to note is the forecast of increased losses next year, suggesting all may not be well at Vir Biotechnology. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. The consensus price target held steady at US$32.00, with the latest estimates not enough to have an impact on their price targets.

With that in mind, we wouldn't be too quick to come to a conclusion on Vir Biotechnology. Long-term earnings power is much more important than next year's profits. At Simply Wall St, we have a full range of analyst estimates for Vir Biotechnology going out to 2024, and you can see them free on our platform here..

Story continues

It is also worth noting that we have found 3 warning signs for Vir Biotechnology (1 is concerning!) that you need to take into consideration.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

See the rest here:
Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo Finance

In a significant development, the department of biotechnology in Union Ministry of Science and Technology, has sanctioned 20 seats to Baba Ghulam Shah Badshah University (BGSBU) Rajouri.

The intake had been sanctioned for M.sc biotechnology program under DBT-PG teaching program for the initial duration of five years.

This will carry a monthly stipend of Rs.5000 and dissertation grant of Rs 50,000 to each students in addition to other infrastructural support, an official at BGSBU said.

He said the admission to this program will be done through a centralized entrance test to be conducted by regional centre for Biotechnology, Faridabad.

Examination centres will be set up in Jammu and Srinagar division for the students who aspire to pursue the course, the official said.

The official said the details of centralized entrance test are available on http://www.rcb.res.in/GATB and also BGSBU website http://www.bgsbu.ac.in.

The last date for the online applications for this test has been fixed as June 18 and the test is scheduled to be held on June 30, 2020, the official said.

With the sanction of 20 seats for BGSBU, the candidates who have applied for M.Sc Biotechnology program of BGSBU will now be required to appear in the centralized entrance tests as well.

BGSBU will not conduct any entrance test for this program in view of new entrance test guidelines from DBT, he said.

Continued here:
BGSBU gets 20 seats for department of Biotechnology from Union Ministry of Science and Technology - Greater Kashmir

Lets start up with the current stock price of Vir Biotechnology, Inc. (VIR), which is $31.41 to be very precise. The Stock rose vividly during the last session to $33.45 after opening rate of $33.1 while the lowest price it went was recorded $30.5 before closing at $32.72.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Vir Biotechnology, Inc. shares are logging -58.13% during the 52-week period from high price, and 169.57% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $11.65 and $75.00.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 498248 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Vir Biotechnology, Inc. (VIR) recorded performance in the market was 160.20%, having the revenues showcasing 53.54% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 3.47B, as it employees total of 229 workers.

During the last month, 3 analysts gave the Vir Biotechnology, Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 1 analysts were recommending to HOLD this stock, 1 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 25.10, with a change in the price was noted +18.22. In a similar fashion, Vir Biotechnology, Inc. posted a movement of +133.93% for the period of last 100 days, recording 821,416 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for VIR is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Raw Stochastic average of Vir Biotechnology, Inc. in the period of last 50 days is set at 26.69%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 36.79%. In the last 20 days, the companys Stochastic %K was 42.39% and its Stochastic %D was recorded 42.40%.

Lets take a glance in the erstwhile performances of Vir Biotechnology, Inc., multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 160.20%. The shares increased approximately by 1.71% in the 7-day charts and went up by 7.10% in the period of the last 30 days. Common stock shares were driven by 53.54% during last recorded quarter.

Continue reading here:
Analysts Mean recommendation for Vir Biotechnology, Inc. (VIR) was 3.20: Is this the key time? - The InvestChronicle

The 72 rating InvestorsObserver gives to Zymeworks Inc (ZYME) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 75 percent of stocks in the Biotechnology industry, ZYMEs 72 overall rating means the stock scores better than 72 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Zymeworks Inc (ZYME) stock is higher by 1.57% while the S&P 500 is down -1.97% as of 11:26 AM on Monday, Jun 15. ZYME is higher by $0.53 from the previous closing price of $34.15 on volume of 94,857 shares. Over the past year the S&P 500 is higher by 3.17% while ZYME is higher by 68.02%. ZYME lost -$3.88 per share the over the last 12 months.

To screen for more stocks like ZYME click here.

More here:
Is Zymeworks Inc (ZYME) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

The First Trust Nasdaq UCITS Cybersecurity ETF is based on the liquidity-weighted Nasdaq CTA Cybersecurity index

First Trust has expanded its thematic ETF range with the launch of two funds offering exposure to cybersecurity and biotechnology through a UCITS structure, available on the London Stock Exchange.

The First Trust Nasdaq UCITS Cybersecurity ETF (CIBR) and the First Trust NYSE Arca Biotechnology UCITS ETF (FBT) will each be accessible to investors for a total expense ratio of 0.6% and are rebalanced quarterly.

First Trust brings best-selling US ETF to the UK

CIBR is based on the liquidity-weighted Nasdaq CTA Cybersecurity index, to be included on which a security must be listed on a global stock exchange, hold a minimum market cap of $250m and have three-month average daily dollar trading volume of $1m. It must also have a minimum free float of 20%.

Alongside companies engaged in the cybersecurity segment of the technology and industrials sector, the index includes those primarily involved in the "building, implementation and management of security protocols applied to private and public networks, computers and mobile devices in order to provide protection of the integrity of data and network operations".

Re-evaluated semi-annually and rebalanced quarterly, each security is capped at 6% weighting and the index never holds more than five securities at this level.

Gregg Guerin, senior product specialist, said: "Cyber crime had already been on the rise but has been greatly accelerated by the Covid-19 crisis pushing millions of people to work remotely, the importance of a secure internet is now, more than ever, absolutely paramount."

Cameron Lilja, vice president and head of research and development for Nasdaq Global Indexes, said: "We are currently seeing enormous growth, exacerbated by the Covid-19 pandemic, in sophisticated technologies such as cloud computing, artificial intelligence, big data and analytics.

"This growth has been matched by an increasing requirement for effective cybersecurity solutions, and the Nasdaq CTA Cybersecurity index offers an effective method for tracking these trends."

FBT will track the NYSE Biotechnology index and is designed to track the performance of a cross section of 30 leading firms within the biotechnology industry, primarily involved in "the use of biological processes to develop products or provide services", including recombinant DNA technology, molecular biology, genetic engineering and genomics.

The cyber security opportunities emerging from booming 'bad actor' activity

Guerin said: "The outlook for investing here is positive with impending drug launches, cost-cutting efforts, an aging population, increasing health care spending, increased merger and acquisition activity as well as potential expansion into emerging markets."

Rupert Haddon, managing director and head of sales and distribution, added: "Cybersecurity and biotechnology are two of the world's fastest growing themes and we are incredibly excited to be adding to our suite of innovative thematic UCITS ETFs, which should give investors precise tools to better express their own investment beliefs."

See more here:
First Trust expands thematic ETF range with two launches - Investment Week

The 73 rating InvestorsObserver gives to Iovance Biotherapeutics Inc (IOVA) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 75 percent of stocks in the Biotechnology industry, IOVAs 73 overall rating means the stock scores better than 73 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 73 would rank higher than 73 percent of all stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Iovance Biotherapeutics Inc (IOVA) stock is trading at $31.32 as of 12:57 PM on Friday, May 29, a decline of -$1.34, or -4.1% from the previous closing price of $32.66. The stock has traded between $31.17 and $33.13 so far today. Volume today is more active than usual. So far 5,849,000 shares have traded compared to average volume of 1,791,534 shares.

To screen for more stocks like IOVA click here.

Read more from the original source:
Is Iovance Biotherapeutics Inc (IOVA) Stock a Good Buy in Biotechnology - InvestorsObserver

SAN FRANCISCO, May 28, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that members of its senior management team will participate in the upcoming Goldman Sachs 41st Annual Global Healthcare Conference.

Goldman Sachs 41st Annual Global Healthcare Conference

Date: June 11, 2020Fireside Chat Time: 3:50 PM E.T. Location: Virtual

A live audio webcast of the fireside chat will be available through the Investors & Media section of UNITYs website. An archived replay will be available for 90 days following the event.

About UNITYUNITY is developing therapeutics to extend healthspan with an initial focus on cellular senescence. UNITY believes that the accumulation of senescent cells is a fundamental mechanism of aging and a driver of many common age-related diseases. Cellular senescence is a natural biological state in which a cell permanently halts division. As senescent cells accumulate with age, they begin secreting inflammatory factors, proteases, fibrotic factors, and growth factors, that disturb the tissue micro-environment. This collection of secreted proteins is referred to as the Senescence Associated Secretory Phenotype, or SASP. UNITY is developing senolytic medicines to eliminate senescent cells and thereby stop the production of the SASP, which UNITY believes addresses a root cause of age-related diseases. By stopping the production of the SASP at it source, UNITY believes senolytic medicines could slow, halt, or reverse diseases such as osteoarthritis and age-related eye diseases. More information is available atwww.unitybiotechnology.comor follow us onTwitter.

Investors Endurance AdvisorsMike Zanonimzanoni@enduranceadvisors.com

Media Canale CommunicationsJason Sparkjason@canalecomm.com

See the rest here:
UNITY Biotechnology to Participate in the Goldman Sachs 41st Annual Global Healthcare Conference - Yahoo Finance

Worldwide Agricultural Biotechnology Market, [Forecast 2020-2029] Succinct Study Report is in-depth survey on the current state of the global Agricultural Biotechnology industry with focus on short term and long term impact analysis of COVID-19/CORONAVIRUS. The report provides key statistics on the market status of the Agricultural Biotechnology manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.

The Agricultural Biotechnology Market report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Vital key players profiled in the report include KWS SAAT SE & Co. KGaA, ChemChina, Limagrain, Nufarm, Marrone Bio Innovations, Performance Plants Inc., Corteva, ADAMA Ltd, MITSUI & CO., LTD, Evogene Ltd., Valent BioSciences LLC, Bayer AG. Company profile includes assign such as company summary, SWOT analysis and current developments, financial summary, product specifications, production value, business strategy and planning. This report analyzes the top players in global market, and splits the Agricultural Biotechnology market by application, organism type, and regions and countries.

|| Access insightful study with over 100+ pages, list of tables & figures, profiling 10+ companies. Ask for Free Sample Copy(PDF) @https://marketresearch.biz/report/agricultural-biotechnology-market/request-sample

Through the statistical analysis, the report depicts the global total market of the Agricultural Biotechnology industry including capacity, production value, cost/profit, supply/demand, production and import/export. The total market is further divided by company, by country, and by application/type for the competitive landscape analysis. The report then estimates the 2020-2029 market development trends of the Agricultural Biotechnology industry. Analysis of upstream raw materials, downstream demand and current market dynamics is also carried out in this report.

In the end, the report makes some important proposals for a new project of the Agricultural Biotechnology Industry before evaluating its feasibility. Overall, the report provides an in-depth insight into the 2020-2029 global Agricultural Biotechnology industry covering all important parameters.

The Final Report will cover the impact analysis of COVID-19 on this industry (Global and Regional Market).

>>>>Download Here- Short Term & Long Term Impact Analysis of Agricultural Biotechnology Market<<<<

Promising Regions & Countries Mentioned In The Agricultural Biotechnology Market Report:

North America (U.S. & Canada)

Latin America (Brazil, Mexico, Argentina, Rest of Latin America)

Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe)

Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific)

The Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of The Middle East and Africa)

Years Considered For This Report:

Historical Years :2013-2018

Base Year :2019

Estimated Year :2020

Forecast Period: 2020-2029

A complete value chain of the global Agricultural Biotechnology Market is presented in the research report. It is associated with the review of the downstream and upstream components of the Agricultural Biotechnology Market. The market is bifurcated on the basis of the categories of products and the customer application segments. The market analysis demonstrates the expansion of each segment of the global Agricultural Biotechnology Market. The research report assists the user in taking a decisive step that will be a milestone in developing and expanding their businesses in the global Agricultural Biotechnology Market.

For any special requirements about this report[Click Here- For Enquiry & Report Customization]please let us know and we can provide custom reports.

Key Answers Captured in Report?

Which geography would have better demand for products/services?

What are the strategies adopted by big players in the regional market?

Which country would see the steep rise in CAGR & year-on-year (Y-O-Y) growth?

What is the current & expected market size in the next five years?

What is the market feasibility for long term investment?

What opportunity the country would offer for existing and new players in the market?

What is the risk involved for suppliers in the geography?

What factors would drive the demand for the product/service in the near future?

What is the impact analysis of various factors in market growth?

There Are 13 Chapters To Thoroughly Display The Agricultural Biotechnology Market:

Chapter 1:Global Agricultural Biotechnology Market Overview, Product Overview, Market Segmentation, Market Overview of Regions, Market Dynamics, Limitations, Opportunities and Industry News and Policies.

Chapter 2:Global Agricultural Biotechnology Market Chain Analysis, Upstream Raw Material Suppliers, Major Players, Production Process Analysis, Cost Analysis, Market Channels and Major Downstream Buyers.

Chapter 3:Value Analysis, Production, Growth Rate and Price Analysis by Type of Agricultural Biotechnology.

Chapter 4:Downstream Characteristics, Consumption and Market Share by Application of Agricultural Biotechnology.

Chapter 5:Production Volume, Price, Gross Margin, and Revenue ($) of Agricultural Biotechnology by Regions (2013-2020).

Chapter 6:Agricultural Biotechnology Production, Consumption, Export and Import by Regions (2013-2020).

Chapter 7:Agricultural Biotechnology Market Status and SWOT Analysis by Regions.

Chapter 8:Global Competitive Landscape, Product Introduction, Company Profiles, Market Distribution Status by Players of Agricultural Biotechnology.

Chapter 9:Agricultural Biotechnology Market Analysis and Forecast by Type and Application (2020-2029).

Chapter 10:Global Market Analysis and Forecast by Regions (2020-2029).

Chapter 11:Global Industry Characteristics, Key Factors, New Entrants SWOT Analysis, Investment Feasibility Analysis.

Chapter 12:Market Conclusion of the Whole Report.

Chapter 13:Appendix Such as Methodology and Data Resources of This Research

....For Detailed InformationClick Here For Complete TOC

Why MarketResearch.Biz?

Robust research methodology of Agricultural Biotechnology market

Technically renowned study with overall Agricultural Biotechnology industry know-how

Focus on Agricultural Biotechnology drivers, restraints, opportunities, and threats till 2029

Based on complete research, we offer the clear view of real Agricultural Biotechnology market scenario and help clients with making an important business judgment

A comprehensive archive of Agricultural Biotechnology market research reports to meet our clients needs

Contact Us:

Mr. Benni Johnson ([emailprotected])

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300

New York City, NY 10170,

United States

Website:https://marketresearch.biz

Go here to read the rest:
Concise Report 2020: Agricultural Biotechnology Market Competitive Landscape and Industrial Growth| The Impact of COVID-19 Disruption During 2029 -...

GARCHING & MUNICH, Germany--(BUSINESS WIRE)--ITM Isotopen Technologien Mnchen AG (ITM), a biotechnology and radiopharmaceutical group of companies, today announced the change of name of its subsidiary ITG Isotope Technologies Garching GmbH. With effect from May 28, 2020, the company responsible specifically for the production of medical isotopes within the ITM Group will operate under the name ITM Medical Isotopes GmbH. The background to the decision is to present a uniform external image of the ITM group of companies, which, alongside ITM Medical Isotopes GmbH, includes among others the highly specialized companies ITM Oncologics GmbH and ITM Solucin GmbH.

The change of name will have no other impact on business partners, customers and staff. The legal form of the company and the ownership structure will remain unchanged. The fields of activity of radioisotope production, the product portfolio and all contracts concluded up to the rebranding will remain unchanged under the new company name. The head office address, the commercial register number and all known contact partners will remain unchanged.

ITG Isotope Technologies Garching GmbH, or ITM Medical Isotopes GmbH, is a 100% subsidiary of ITM Isotopen Technologien Mnchen AG. Over the course of the companys 16-year history, from a start-up housed on the Technical University of Munich (TUM) site, ITM has established itself as a worldwide biotechnology and radiopharmaceutical group of companies in Targeted Radionuclide Therapy with a global distribution network. ITM develops, produces and distributes radiopharmaceuticals and medical radioisotopes for the diagnosis and therapy of cancer. The current product portfolio and focus of research includes targeted candidates for the treatment of neuroendocrine tumors, glioblastoma, osteosarcoma and bone metastases, as well as folate receptor positive tumors such as lung, ovarian or breast cancer.

We are proud of everything that we have managed to achieve jointly as the ITM group of companies over the past 16 years. We now supply hospitals, and hence patients, worldwide with our radiopharmaceuticals and medical radioisotopes for targeted cancer therapy, says Steffen Schuster, CEO of ITM. The pooling of our subsidiaries expertise will now also be reflected nominally by the unification under the ITM family brand. This will strengthen our market position and will allow all business areas to benefit equally from our first-class reputation as an international biotechnology and radiopharmaceutical group of companies, adds Steffen Schuster, CEO of ITM.

- End -

Read more from the original source:
Rebranding: ITG Isotope Technologies Garching GmbH will become ITM Medical Isotopes GmbH - Business Wire